Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

Journal for immunotherapy of cancer·2026
Same author

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].

European urology open science·2026
Same author

A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.

Clinical immunology (Orlando, Fla.)·2026
Same author

Recurrent respiratory papillomatosis: is patient well-being related to anatomical manifestation?

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

The Voice of Cantú: Lower Voice Pitch Is a New Phenotypic Feature of Cantú Syndrome.

American journal of medical genetics. Part A·2026
Same author

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials.

European urology open science·2026
Same journal

Congenital Acute Lymphoblastic Leukaemia with Hyperleucocytosis in a Full-Term Neonate: A Case Report.

Case reports in oncology·2026
Same journal

Breast Mass as the Initial Presentation of B-Cell Acute Lymphoblastic Leukemia: A Case Report.

Case reports in oncology·2026
Same journal

Primary Rectal Burkitt Lymphoma in a Child: A Case Report and a Review of the Literature.

Case reports in oncology·2026
Same journal

Recurrence after Long-Term Use of Poly ADP-Ribose Polymerase Inhibitors Triggered by Therapy-Related Myeloid Neoplasms: A Case Report.

Case reports in oncology·2026
Same journal

Metastatic Involvement of the Ureter from Recurrent Pancreatic Cancer in a Patient with Multiple prior Malignancies: A Case Report.

Case reports in oncology·2026
Same journal

The Rare Trio: Concomitant Bone Marrow Involvement by Smoldering Myeloma and Systemic Mastocytosis with an Associated Hematologic Neoplasm and ALECT-2 Renal Amyloidosis - A Case Report and Literature Review.

Case reports in oncology·2026
See all related articles

Related Experiment Videos

Irinotecan-induced dysarthria.

Albertine J Dressel1, Johannes C van der Mijn, Ijke J Aalders

  • 1Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.

Case Reports in Oncology
|March 2, 2012
PubMed
Summary
This summary is machine-generated.

A 46-year-old patient experienced temporary speech difficulties after irinotecan chemotherapy for rectal cancer. This transient dysarthria is likely due to irinotecan

Keywords:
Colorectal cancerDysarthriaIrinotecan

Related Experiment Videos

Area of Science:

  • Oncology
  • Neurology
  • Pharmacology

Background:

  • Colorectal carcinomas are common, often treated with palliative chemotherapy for metastatic disease.
  • Second-line therapy with irinotecan is a standard treatment option.

Observation:

  • A 46-year-old patient with metastatic rectal carcinoma developed isolated transient dysarthria after each irinotecan administration.
  • Brain MRI showed normal findings, ruling out structural neurological causes.

Findings:

  • Detailed evaluation indicated dysarthria stemmed from impaired fine motor control of the tongue and reduced speech power.
  • The mechanism is suspected to involve irinotecan's anticholinesterase activity affecting cholinergic pathways crucial for hypoglossal nerve function.

Implications:

  • This case highlights a potential, reversible neurological side effect of irinotecan.
  • Understanding this mechanism may inform management strategies for patients receiving irinotecan-based chemotherapy.